08:14 AM EDT, 09/18/2025 (MT Newswires) -- Launch One Acquisition's ( LPAA ) merger target Minovia Therapeutics said Thursday that the US Food and Drug Administration has granted fast track designation to its lead investigational compound, MNV-201, for the treatment of Myelodysplastic syndrome.

The designation is in addition to existing FDA fast track and rare pediatric disease designations for MNV-201 to treat Pearson syndrome, the company said.

Following the expected closing of the merger with Launch One in late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol, the company added.

Launch One's shares were up 2.3% in recent Thursday premarket activity.